W
WAVEMAN · COMPANY
LXEO · Lexeo Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

LXEO

Lexeo Therapeutics, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001907108
FORM 144 · 7☆ WATCH
INSIDER NET · 180D
-$636.3K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
89
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$636.3K over 180 days
-$299.8K over 90 days
below 57% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
89 funds added or opened last quarter
more than 61% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
20.8% of shares outstanding short · 16.9 days to cover · settled 2026-07-31
more than 96% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$636.3K across 4 people in 180 days.
89 funds added or opened positions in the latest 13F quarter, of 144 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +2.1%
+2.1%12M
-14%+31%+77%+122%2025-092025-102025-122026-032026-052026-072026-09 2026-04-06 · Townsend Richard Nolan sold $312.9K2026-07-01 · Townsend Richard Nolan sold $116.2K2025-10-17 · Townsend Richard Nolan sold $116.1K2026-07-01 · Bhalla Narinder Pal sold $98.6K2026-02-18 · Townsend Richard Nolan sold $64.9K2025-10-17 · See Tai Sandi sold $34.4K2025-10-17 · Robertson Jenny sold $31.2K2025-10-17 · Adler Eric sold $29.9K2026-07-01 · Otero Jose Manuel sold $20.9K2026-07-01 · Tamayo Louis Edward sold $20.8K2026-08-18 · Tamayo Louis Edward sold $20.2K2026-02-18 · Otero Jose Manuel sold $19.3K2025-10-17 · Otero Jose Manuel sold $18.7K2026-05-18 · Townsend Richard Nolan sold $16.9K2026-08-18 · Townsend Richard Nolan sold $16.6K2025-11-18 · Townsend Richard Nolan sold $10.4K2025-11-18 · Otero Jose Manuel sold $6.7K2026-05-18 · Otero Jose Manuel sold $6.6K2026-08-18 · Otero Jose Manuel sold $6.5K2025-11-18 · Adler Eric sold $5.7K2025-11-18 · Robertson Jenny sold $5.1K2025-11-18 · See Tai Sandi sold $3.6K2025-10-17 · Townsend Richard Nolan sold $1.4K2025-10-17 · See Tai Sandi sold $4212025-10-17 · Robertson Jenny sold $3822025-10-17 · Adler Eric sold $3632025-10-17 · Otero Jose Manuel sold $2292026-08-18 · Tamayo Louis Edward filed to sell $20.2K2026-08-18 · Otero Jose Manuel filed to sell $6.5K2026-08-18 · Townsend Richard Nolan filed to sell $16.6K2026-07-01 · Bhalla Narinder Pal filed to sell $98.7K2026-07-01 · Townsend Richard Nolan filed to sell $116.2K2026-07-01 · Tamayo Louis Edward filed to sell $20.8K2026-07-01 · Otero Jose Manuel filed to sell $20.9K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $636.3K sold by insiders over 180 days, 89 funds added last quarter, $299.8K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Lexeo Therapeutics, Inc. insiders sold a net $636.3K of stock across 58 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Tamayo Louis Edward
Chief Financial Officer
SELL
2026-08-18
4,117.0
$20.2K
Townsend Richard Nolan
Chief Executive Officer
SELL
2026-08-18
3,345.0
$16.6K
Otero Jose Manuel
Chief Operating Officer
SELL
2026-08-18
1,304.0
$6.5K
Bhalla Narinder Pal
Chief Medical Officer
SELL
2026-07-01
22,306.0
$98.6K
Townsend Richard Nolan
Chief Executive Officer
SELL
2026-07-01
25,947.0
$116.2K
58 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 53 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
MONTANOVA CAPITAL, LLC
6,384,200.0 sh
$29.7M
Affinity Asset Advisors, LLC
5,807,611.0 sh
$27.0M
BlackRock, Inc.
5,739,455.0 sh
$26.7M
RA CAPITAL MANAGEMENT, L.P.
5,000,000.0 sh
$23.3M
Frazier Life Sciences Management, L.P.
4,824,725.0 sh
$22.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Tamayo Louis Edward
FILED 2026-08-18
$20.2K
Otero Jose Manuel
FILED 2026-08-18
$6.5K
Townsend Richard Nolan
FILED 2026-08-18
$16.6K
Bhalla Narinder Pal
FILED 2026-07-01
$98.7K
Townsend Richard Nolan
FILED 2026-07-01
$116.2K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Virtus Biotech Clinical Trials Etf
$160.9K POSITION · AS OF 2026-04-30
0.4%
Invesco Dorsey Wright SmallCap Momentum ETF
$1.2M POSITION · AS OF 2026-02-28
0.3%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$10.7M POSITION · AS OF 2026-03-31
0.1%
PROFUND VP BIOTECHNOLOGY
$59.5K POSITION · AS OF 2026-03-31
0.1%
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund
$223.4K POSITION · AS OF 2026-03-31
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
$618.4K POSITION · AS OF 2026-04-30
0.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 8 registered trials, 7 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
1
Phase 2
1 ACTIVE
3
Not applicable
3 ACTIVE
3
Multi-phase
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE———$654.0K
OPERATING INCOME$-109.3M$-105.8M$-68.5M$-60.5M
NET INCOME$-100.0M$-98.3M$-66.4M$-59.3M
EPS (DILUTED)-1.86-3.09-12.40-36.36
OPERATING CASH FLOW$-98.6M$-81.2M$-59.5M$-54.6M
CASH$63.0M$35.0M$121.5M$77.3M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →